Growth differentiation factor 15 induces cisplatin resistance through upregulation of xCT expression and glutathione synthesis in gastric cancer

Wang, Sheng-Fan; Chang, Yuh‐Lih; Fang, Wen-Liang; Li, Anna Fen–Yau; Chen, Chian-Feng; Yeh, Ta‐Sen; Hung, Giun Yi; Huang, Kai

doi:10.1111/cas.15869

Cited by 13 publications

(2 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GSH is reported to inhibit cisplatin-mediated cytotoxicity and activate ABC transporter activity thus inducing resistance in many cancers (L1210 leukemia cells etc.) against cisplatin [ 310 , 311 ]. This opens a new treatment window of targeting GSH (like buthionine-sulfoximine) that might increase the sensitivity of resistant cancer cells toward cisplatin.…”

Section: Metabolic Changes/regulations Govern Drug Resistance In Canc...mentioning

confidence: 99%

Unveiling the mechanisms and challenges of cancer drug resistance

Khan,

Fatima,

Aisha

et al. 2024

Cell Commun Signal

View full text Add to dashboard Cite

Cancer treatment faces many hurdles and resistance is one among them. Anti-cancer treatment strategies are evolving due to innate and acquired resistance capacity, governed by genetic, epigenetic, proteomic, metabolic, or microenvironmental cues that ultimately enable selected cancer cells to survive and progress under unfavorable conditions. Although the mechanism of drug resistance is being widely studied to generate new target-based drugs with better potency than existing ones. However, due to the broader flexibility in acquired drug resistance, advanced therapeutic options with better efficacy need to be explored. Combination therapy is an alternative with a better success rate though the risk of amplified side effects is commonplace. Moreover, recent groundbreaking precision immune therapy is one of the ways to overcome drug resistance and has revolutionized anticancer therapy to a greater extent with the only limitation of being individual-specific and needs further attention. This review will focus on the challenges and strategies opted by cancer cells to withstand the current therapies at the molecular level and also highlights the emerging therapeutic options -like immunological, and stem cell-based options that may prove to have better potential to challenge the existing problem of therapy resistance.

show abstract

Section: Metabolic Changes/regulations Govern Drug Resistance In Canc...mentioning

confidence: 99%

Unveiling the mechanisms and challenges of cancer drug resistance

Khan,

Fatima,

Aisha

et al. 2024

Cell Commun Signal

View full text Add to dashboard Cite

show abstract

“…GDF15 might be implicated in cancer progression and is also regulated by ISR [ 33 ]. Recent evidence suggests that GDF15 might be essential for cell proliferation, cell migration, and cisplatin resistance in human gastric cancer [ 142 ]. In addition, GDF15 might be a promising targetable immune checkpoint because it can inhibit dendritic cell maturation and immune cell infiltration [ 143 ].…”

Section: Introductionmentioning

confidence: 99%

Role of mitochondrial alterations in human cancer progression and cancer immunity

Wang,

Tseng,

Lee

2023

J Biomed Sci

View full text Add to dashboard Cite

Dysregulating cellular metabolism is one of the emerging cancer hallmarks. Mitochondria are essential organelles responsible for numerous physiologic processes, such as energy production, cellular metabolism, apoptosis, and calcium and redox homeostasis. Although the “Warburg effect,” in which cancer cells prefer aerobic glycolysis even under normal oxygen circumstances, was proposed a century ago, how mitochondrial dysfunction contributes to cancer progression is still unclear. This review discusses recent progress in the alterations of mitochondrial DNA (mtDNA) and mitochondrial dynamics in cancer malignant progression. Moreover, we integrate the possible regulatory mechanism of mitochondrial dysfunction–mediated mitochondrial retrograde signaling pathways, including mitochondrion-derived molecules (reactive oxygen species, calcium, oncometabolites, and mtDNA) and mitochondrial stress response pathways (mitochondrial unfolded protein response and integrated stress response) in cancer progression and provide the possible therapeutic targets. Furthermore, we discuss recent findings on the role of mitochondria in the immune regulatory function of immune cells and reveal the impact of the tumor microenvironment and metabolism remodeling on cancer immunity. Targeting the mitochondria and metabolism might improve cancer immunotherapy. These findings suggest that targeting mitochondrial retrograde signaling in cancer malignancy and modulating metabolism and mitochondria in cancer immunity might be promising treatment strategies for cancer patients and provide precise and personalized medicine against cancer.

show abstract